|
AU2017266911B2
(en)
*
|
2016-05-18 |
2021-09-02 |
Array Biopharma, Inc. |
KRas G12C inhibitors
|
|
SG11202004427TA
(en)
*
|
2017-11-15 |
2020-06-29 |
Mirati Therapeutics Inc |
Kras g12c inhibitors
|
|
US11090304B2
(en)
*
|
2018-05-04 |
2021-08-17 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
|
EP3790551A4
(en)
|
2018-05-07 |
2022-03-09 |
Mirati Therapeutics, Inc. |
Kras g12c inhibitors
|
|
TW202012415A
(zh)
|
2018-05-08 |
2020-04-01 |
瑞典商阿斯特捷利康公司 |
化學化合物
|
|
ES2961253T3
(es)
*
|
2018-08-31 |
2024-03-11 |
Mirati Therapeutics Inc |
Inhibidores de KRas G12C
|
|
CA3112043A1
(en)
|
2018-09-10 |
2020-03-19 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
WO2020055760A1
(en)
|
2018-09-10 |
2020-03-19 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
RS66727B1
(sr)
|
2018-09-10 |
2025-05-30 |
Mirati Therapeutics Inc |
Kombinacija dasatiniba i adagrasiba za primenu u lečenju nesitnoćelijskog kancera pluća
|
|
EP3849535A4
(en)
|
2018-09-10 |
2022-06-29 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
WO2020055758A1
(en)
|
2018-09-10 |
2020-03-19 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
WO2020085504A1
(ja)
|
2018-10-26 |
2020-04-30 |
大鵬薬品工業株式会社 |
光照射ザンドマイヤー反応を用いたクロロアゾールカルボキシレート誘導体の製造方法
|
|
CA3087089C
(en)
|
2018-11-09 |
2023-09-12 |
F. Hoffmann-La Roche Ag |
Fused ring compounds
|
|
CA3112129A1
(en)
|
2018-12-05 |
2020-06-11 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
JP7592601B2
(ja)
|
2019-01-10 |
2024-12-02 |
ミラティ セラピューティクス， インコーポレイテッド |
Ｋｒａｓ ｇ１２ｃ阻害剤
|
|
JP7572958B2
(ja)
|
2019-02-12 |
2024-10-24 |
ノバルティス アーゲー |
Ｔｎｏ１５５及びｋｒａｓｇ１２ｃ阻害剤を含む医薬組合せ
|
|
BR112021017408A2
(pt)
|
2019-03-05 |
2022-01-18 |
Astrazeneca Ab |
Compostos tricíclicos fundidos úteis como agentes anticancerosos
|
|
CN113874374B
(zh)
*
|
2019-05-24 |
2024-12-27 |
江苏恒瑞医药股份有限公司 |
氢化吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用
|
|
CN118745177A
(zh)
*
|
2019-05-29 |
2024-10-08 |
上海翰森生物医药科技有限公司 |
含氮杂环类衍生物调节剂、其制备方法和应用
|
|
CN112047939B
(zh)
*
|
2019-06-06 |
2023-05-02 |
江苏先声药业有限公司 |
一种具有抗肿瘤活性的四氢吡啶并嘧啶类化合物
|
|
CN112300153B
(zh)
*
|
2019-07-26 |
2023-06-13 |
博瑞生物医药（苏州）股份有限公司 |
一种杂环化合物、药物组合物和用途
|
|
EP4011886A4
(en)
*
|
2019-08-02 |
2023-07-26 |
Shanghai Jemincare Pharmaceuticals Co., Ltd. |
TETRACYCLIC COMPOUND, METHOD FOR PREPARATION AND USE
|
|
CN112341457A
(zh)
*
|
2019-08-07 |
2021-02-09 |
北京加科思新药研发有限公司 |
Kras突变蛋白抑制剂
|
|
CN112390788A
(zh)
*
|
2019-08-13 |
2021-02-23 |
苏州闻天医药科技有限公司 |
一种用于抑制krasg12c突变蛋白的化合物及其制备方法和用途
|
|
CN112390797A
(zh)
*
|
2019-08-15 |
2021-02-23 |
微境生物医药科技(上海)有限公司 |
新型螺环类K-Ras G12C抑制剂
|
|
CN114616232A
(zh)
*
|
2019-09-06 |
2022-06-10 |
正大天晴药业集团南京顺欣制药有限公司 |
氮杂环庚烷并嘧啶类衍生物及其医药用途
|
|
US20220402916A1
(en)
*
|
2019-09-18 |
2022-12-22 |
Merck Sharp & Dohme Corp. |
Small molecule inhibitors of kras g12c mutant
|
|
US12122787B2
(en)
|
2019-09-20 |
2024-10-22 |
Shanghai Jemincare Pharmaceuticals Co., Ltd |
Fused pyridone compound, and preparation method therefor and use thereof
|
|
KR20220091480A
(ko)
*
|
2019-09-24 |
2022-06-30 |
미라티 테라퓨틱스, 인크. |
병용 요법
|
|
TW202115062A
(zh)
*
|
2019-09-25 |
2021-04-16 |
大陸商北京加科思新藥研發有限公司 |
Kras突變蛋白抑制劑
|
|
BR112022006394A2
(pt)
|
2019-10-02 |
2022-07-26 |
Tolremo Therapeutics Ag |
Derivados heterocíclicos, composições farmacêuticas e seu uso no tratamento ou melhora do câncer
|
|
US20230257374A1
(en)
*
|
2019-10-10 |
2023-08-17 |
Innovent Biologics (Suzhou) Co., Ltd. |
Novel kras g12c protein inhibitor, preparation method therefor, and use thereof
|
|
CN112694475B
(zh)
*
|
2019-10-23 |
2025-09-23 |
苏州泽璟生物制药股份有限公司 |
环烷基类和杂环烷基类抑制剂及其制备方法和应用
|
|
MX2022005053A
(es)
|
2019-10-28 |
2022-05-18 |
Merck Sharp & Dohme Llc |
Inhibidores de peque?as moleculas de mutante g12c de kras.
|
|
LT4053118T
(lt)
*
|
2019-10-30 |
2024-12-10 |
Genfleet Therapeutics (Shanghai) Inc. |
Pakeistas heterociklinis junginys su sujungtais žiedais, jo paruošimo būdas ir naudojimas farmacijoje
|
|
CN115873067A
(zh)
|
2019-11-04 |
2023-03-31 |
锐新医药公司 |
Ras抑制剂
|
|
AU2020379734B2
(en)
|
2019-11-04 |
2025-11-20 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
TW202132315A
(zh)
|
2019-11-04 |
2021-09-01 |
美商銳新醫藥公司 |
Ras 抑制劑
|
|
WO2021088458A1
(en)
*
|
2019-11-04 |
2021-05-14 |
Jacobio Pharmaceuticals Co., Ltd. |
Kras mutant protein inhibitor
|
|
CN112778301A
(zh)
*
|
2019-11-07 |
2021-05-11 |
苏州泽璟生物制药股份有限公司 |
四氢吡啶并嘧啶类抑制剂及其制备方法和应用
|
|
CN112824410A
(zh)
*
|
2019-11-21 |
2021-05-21 |
苏州泽璟生物制药股份有限公司 |
氮杂七元环类抑制剂及其制备方法和应用
|
|
EP4065231A1
(en)
|
2019-11-27 |
2022-10-05 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
|
EP4065125A4
(en)
|
2019-11-27 |
2024-01-03 |
Turning Point Therapeutics, Inc. |
COMBINATION THERAPY WITH DIARYL MACROCYCLIC COMPOUNDS
|
|
WO2021106231A1
(en)
*
|
2019-11-29 |
2021-06-03 |
Taiho Pharmaceutical Co., Ltd. |
A compound having inhibitory activity against kras g12d mutation
|
|
WO2021106230A1
(ja)
|
2019-11-29 |
2021-06-03 |
大鵬薬品工業株式会社 |
新規なフェノール化合物又はその塩
|
|
US20220315598A1
(en)
*
|
2019-12-02 |
2022-10-06 |
Shanghai Yingli Pharmaceutical Co., Ltd |
Oxygen-containing Heterocyclic Compound, Preparation Method Therefor and Use Thereof
|
|
HRP20221301T1
(hr)
|
2019-12-11 |
2022-12-23 |
Eli Lilly And Company |
Inhibitori kras g12c
|
|
CN115192577B
(zh)
|
2019-12-19 |
2024-03-29 |
北京加科思新药研发有限公司 |
Kras突变蛋白抑制剂
|
|
CN113004269B
(zh)
*
|
2019-12-19 |
2024-11-05 |
首药控股(北京)股份有限公司 |
Kras-G12C抑制剂杂环化合物
|
|
AU2020405170A1
(en)
|
2019-12-20 |
2022-06-30 |
Mirati Therapeutics, Inc. |
SOS1 inhibitors
|
|
WO2021120890A1
(en)
|
2019-12-20 |
2021-06-24 |
Novartis Ag |
Pyrazolyl derivatives useful as anti-cancer agents
|
|
CN113045565A
(zh)
*
|
2019-12-27 |
2021-06-29 |
微境生物医药科技(上海)有限公司 |
新型K-Ras G12C抑制剂
|
|
CN112094269B
(zh)
*
|
2020-01-01 |
2021-12-07 |
上海凌达生物医药有限公司 |
一类饱和六元环并杂环类化合物、制备方法和用途
|
|
TWI770760B
(zh)
|
2020-01-08 |
2022-07-11 |
大陸商蘇州亞盛藥業有限公司 |
螺環四氫喹唑啉
|
|
GB202001344D0
(en)
|
2020-01-31 |
2020-03-18 |
Redx Pharma Plc |
Ras Inhibitors
|
|
AU2021224733A1
(en)
*
|
2020-02-20 |
2022-09-01 |
Beta Pharma, Inc. |
Pyridopyrimidine derivatives as KRAS inhibitors
|
|
CN113637005B
(zh)
*
|
2020-02-24 |
2024-05-24 |
泰励生物科技（上海）有限公司 |
用于癌症治疗的kras抑制剂
|
|
WO2023205701A1
(en)
|
2022-04-20 |
2023-10-26 |
Kumquat Biosciences Inc. |
Macrocyclic heterocycles and uses thereof
|
|
KR20250026883A
(ko)
*
|
2020-03-12 |
2025-02-25 |
디3 바이오 (우씨) 컴퍼니, 리미티드 |
피리미도헤테로사이클릭 화합물 및 이의 응용
|
|
CN115427414A
(zh)
*
|
2020-04-28 |
2022-12-02 |
贝达药业股份有限公司 |
稠环化合物及其在医药上的应用
|
|
CN116194456B
(zh)
*
|
2020-04-30 |
2025-08-29 |
上海科州药物股份有限公司 |
作为kras抑制剂的杂环化合物的制备及其应用方法
|
|
US11739102B2
(en)
|
2020-05-13 |
2023-08-29 |
Incyte Corporation |
Fused pyrimidine compounds as KRAS inhibitors
|
|
CN113666923A
(zh)
*
|
2020-05-15 |
2021-11-19 |
苏州泽璟生物制药股份有限公司 |
烷氧基烷基取代杂环基类抑制剂及其制备方法和应用
|
|
JP2023528623A
(ja)
|
2020-06-02 |
2023-07-05 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
がんを治療するための縮合環化２－アミノ－３－シアノチオフェン及び誘導体
|
|
MX2022015272A
(es)
*
|
2020-06-04 |
2023-01-11 |
Antengene Discovery Ltd |
Inhibidores de la proteina kras g12c y usos de estos.
|
|
CN115916194A
(zh)
*
|
2020-06-18 |
2023-04-04 |
锐新医药公司 |
用于延迟、预防和治疗针对ras抑制剂的获得性抗性的方法
|
|
WO2021259972A1
(en)
|
2020-06-24 |
2021-12-30 |
Boehringer Ingelheim International Gmbh |
Anticancer combination therapy comprising a sos1 inhibitor and a kras g12c inhibitor
|
|
MX2022016498A
(es)
*
|
2020-06-25 |
2023-02-23 |
Tolremo Therapeutics Ag |
Una combinacion de un inhibidor de cbp/p300 bromodominio y un inhibidor de kras.
|
|
CN113912608B
(zh)
*
|
2020-07-10 |
2023-07-14 |
江苏恒瑞医药股份有限公司 |
嘧啶并嘧啶酮类衍生物、其制备方法及其在医药上的应用
|
|
CN113980014B
(zh)
*
|
2020-07-27 |
2023-05-12 |
江苏恒瑞医药股份有限公司 |
氢化吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用
|
|
EP4196480A4
(en)
*
|
2020-08-17 |
2024-10-16 |
Betta Pharmaceuticals Co., Ltd |
BICYCLIC COMPOUNDS, COMPOSITIONS AND USE THEREOF
|
|
AU2021331492A1
(en)
|
2020-08-28 |
2023-04-13 |
Kumquat Biosciences Inc. |
Heterocyclic compounds and uses thereof
|
|
US20250195521A1
(en)
|
2020-09-03 |
2025-06-19 |
Revolution Medicines, Inc. |
Use of sos1 inhibitors to treat malignancies with shp2 mutations
|
|
WO2022052895A1
(zh)
|
2020-09-11 |
2022-03-17 |
南京明德新药研发有限公司 |
氮杂环丁烷取代化合物的晶型
|
|
MX2023002942A
(es)
*
|
2020-09-11 |
2023-05-22 |
Mirati Therapeutics Inc |
Formas cristalinas de un inhibidor de kras g12c.
|
|
CN116601151A
(zh)
*
|
2020-09-11 |
2023-08-15 |
米拉蒂治疗股份有限公司 |
Kras g12c抑制剂的晶型
|
|
CN117683049A
(zh)
|
2020-09-15 |
2024-03-12 |
锐新医药公司 |
作为ras抑制剂以治疗癌症的吲哚衍生物
|
|
AU2021347232A1
(en)
|
2020-09-23 |
2023-04-27 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
|
US20220112204A1
(en)
*
|
2020-10-14 |
2022-04-14 |
Accutar Biotechnology Inc. |
Substituted dihydropyranopyrimidine compounds as kras inhibitors
|
|
WO2022087270A1
(en)
|
2020-10-23 |
2022-04-28 |
Mirati Therapeutics, Inc. |
Methods for treatment of lung cancers
|
|
AU2021372796A1
(en)
*
|
2020-10-30 |
2023-06-01 |
Novartis Ag |
New crystalline forms of a kras g12c inhibitor compound
|
|
CN120887884A
(zh)
|
2020-11-06 |
2025-11-04 |
泰励生物科技（上海）有限公司 |
用于癌症治疗的KRas抑制剂
|
|
WO2022109485A1
(en)
*
|
2020-11-23 |
2022-05-27 |
Merck Sharp & Dohme Corp. |
6,7-dihydro-pyrano[2,3-d]pyrimidine inhibitors of kras g12c mutant
|
|
CN114591319B
(zh)
*
|
2020-12-04 |
2024-06-28 |
江苏先声药业有限公司 |
四氢吡啶并嘧啶类衍生物及其用途
|
|
CN116829151A
(zh)
*
|
2020-12-15 |
2023-09-29 |
米拉蒂治疗股份有限公司 |
氮杂喹唑啉泛KRas抑制剂
|
|
CA3198885A1
(en)
|
2020-12-15 |
2022-06-23 |
Xiaolun Wang |
Azaquinazoline pan-kras inhibitors
|
|
WO2022133038A1
(en)
*
|
2020-12-16 |
2022-06-23 |
Mirati Therapeutics, Inc. |
Tetrahydropyridopyrimidine pan-kras inhibitors
|
|
US20230107642A1
(en)
|
2020-12-18 |
2023-04-06 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
|
PE20240545A1
(es)
|
2020-12-18 |
2024-03-19 |
Amphista Therapeutics Ltd |
Moleculas bifuncionales novedosas para la degradacion de proteinas dirigidas
|
|
CN116529249A
(zh)
*
|
2020-12-18 |
2023-08-01 |
正大天晴药业集团股份有限公司 |
吡啶并嘧啶酮类化合物
|
|
WO2022140246A1
(en)
|
2020-12-21 |
2022-06-30 |
Hangzhou Jijing Pharmaceutical Technology Limited |
Methods and compounds for targeted autophagy
|
|
KR20230127256A
(ko)
*
|
2020-12-22 |
2023-08-31 |
노파르티스 아게 |
Kras g12c 억제제를 포함하는 약제학적 조합물 및 암의치료를 위한 kras g12c 억제제의 용도
|
|
CN114716436A
(zh)
*
|
2021-01-04 |
2022-07-08 |
广州百霆医药科技有限公司 |
Kras g12c突变抑制剂及其用途
|
|
US20240092803A1
(en)
*
|
2021-01-08 |
2024-03-21 |
Beigene Switzerland Gmbh |
Bridged compounds as kras g12d inhibitor and degrader and the use thereof
|
|
WO2022165142A1
(en)
*
|
2021-01-29 |
2022-08-04 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
US20250066387A9
(en)
*
|
2021-02-01 |
2025-02-27 |
D3 Bio (Wuxi) Co., Ltd. |
Pyrimidopyran compound
|
|
WO2022171143A1
(zh)
*
|
2021-02-09 |
2022-08-18 |
南京明德新药研发有限公司 |
5,6,7,8-四氢吡啶[3,4-d]嘧啶化合物
|
|
WO2022187527A1
(en)
*
|
2021-03-05 |
2022-09-09 |
Nikang Therapeutics, Inc |
Quinazoline nitrile derivatives as kras inhibitors
|
|
WO2022195355A1
(en)
|
2021-03-15 |
2022-09-22 |
Novartis Ag |
Benzisoxazole derivatives and uses thereof
|
|
CN116801883A
(zh)
*
|
2021-03-18 |
2023-09-22 |
四川科伦博泰生物医药股份有限公司 |
一类杂芳环化合物、其制备方法及用途
|
|
WO2022204112A1
(en)
|
2021-03-22 |
2022-09-29 |
Incyte Corporation |
Imidazole and triazole kras inhibitors
|
|
CN115124524A
(zh)
*
|
2021-03-26 |
2022-09-30 |
浙江海正药业股份有限公司 |
三环类衍生物及其制备方法和用途
|
|
WO2022206724A1
(zh)
*
|
2021-03-30 |
2022-10-06 |
浙江海正药业股份有限公司 |
杂环类衍生物及其制备方法和用途
|
|
WO2022216648A1
(en)
|
2021-04-08 |
2022-10-13 |
Mirati Therapeutics, Inc. |
Combination therapies using prmt5 inhibitors for the treatment of cancer
|
|
JP2024514127A
(ja)
|
2021-04-09 |
2024-03-28 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
抗がん剤療法
|
|
WO2022217042A1
(en)
*
|
2021-04-09 |
2022-10-13 |
Ikena Oncology, Inc. |
Naphthyl-substituted quinoline-4(1h)-ones and related compounds and their use in treating medical conditions
|
|
WO2022223020A1
(zh)
*
|
2021-04-23 |
2022-10-27 |
清华大学 |
靶向活化与失活态kras g12d的抑制剂
|
|
US20230106174A1
(en)
|
2021-05-05 |
2023-04-06 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
EP4334325A1
(en)
|
2021-05-05 |
2024-03-13 |
Revolution Medicines, Inc. |
Ras inhibitors for the treatment of cancer
|
|
JP2024519845A
(ja)
*
|
2021-05-19 |
2024-05-21 |
ジェネンテック， インコーポレイテッド |
併用療法
|
|
WO2022247760A1
(zh)
*
|
2021-05-22 |
2022-12-01 |
上海科州药物研发有限公司 |
作为kras抑制剂的杂环化合物，及其制备和治疗用途
|
|
EP4346826A4
(en)
|
2021-05-27 |
2025-04-30 |
Mirati Therapeutics, Inc. |
COMBINATION THERAPIES
|
|
US20240417408A1
(en)
*
|
2021-05-28 |
2024-12-19 |
Merck Sharp & Dohme Corp. |
Small molecule inhibitors of kras g12c mutant
|
|
EP4347041A1
(en)
*
|
2021-05-28 |
2024-04-10 |
Taiho Pharmaceutical Co., Ltd. |
Small molecule inhibitors of kras mutated proteins
|
|
WO2022261154A1
(en)
|
2021-06-09 |
2022-12-15 |
Eli Lilly And Company |
Substituted fused azines as kras g12d inhibitors
|
|
WO2022266206A1
(en)
|
2021-06-16 |
2022-12-22 |
Erasca, Inc. |
Kras inhibitor conjugates
|
|
CN117529321A
(zh)
*
|
2021-06-18 |
2024-02-06 |
上海德琪医药科技有限公司 |
Erk抑制剂和kras抑制剂的组合及其用途
|
|
TW202317100A
(zh)
|
2021-06-23 |
2023-05-01 |
瑞士商諾華公司 |
包含ｋｒａｓ ｇ１２ｃ抑制劑的藥物組合及其用於治療癌症之用途
|
|
CN117751116A
(zh)
*
|
2021-07-07 |
2024-03-22 |
微境生物医药科技(上海)有限公司 |
作为KRas G12D抑制剂的稠环化合物
|
|
US12441727B2
(en)
|
2021-07-07 |
2025-10-14 |
Incyte Corporation |
Tricyclic compounds as inhibitors of KRAS
|
|
EP4370522A1
(en)
|
2021-07-14 |
2024-05-22 |
Nikang Therapeutics, Inc. |
Alkylidene derivatives as kras inhibitors
|
|
WO2023283933A1
(en)
*
|
2021-07-16 |
2023-01-19 |
Silexon Biotech Co., Ltd. |
Compounds useful as kras g12d inhibitors
|
|
US20250281607A1
(en)
|
2021-07-27 |
2025-09-11 |
Toray Industries, Inc. |
Medicament for treatment and/or prevention of cancer
|
|
CN113527294A
(zh)
*
|
2021-08-25 |
2021-10-22 |
都创(上海)医药开发有限公司 |
Mrtx849化合物的晶型及其制备方法和用途
|
|
CA3229855A1
(en)
|
2021-08-31 |
2023-03-09 |
Incyte Corporation |
Naphthyridine compounds as inhibitors of kras
|
|
AU2022336415A1
(en)
|
2021-09-01 |
2024-01-04 |
Novartis Ag |
Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers
|
|
EP4389751A1
(en)
|
2021-09-03 |
2024-06-26 |
Kumquat Biosciences Inc. |
Heterocyclic compounds and uses thereof
|
|
EP4398897A4
(en)
*
|
2021-09-09 |
2025-10-08 |
Mirati Therapeutics Inc |
PROCESSES AND INTERMEDIATES FOR THE SYNTHESIS OF ADAGRASIB
|
|
WO2023051586A1
(zh)
*
|
2021-09-29 |
2023-04-06 |
先声再明医药有限公司 |
Kras g12d抑制剂化合物及其制备方法和应用
|
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
|
US20250122211A1
(en)
|
2021-10-22 |
2025-04-17 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Nitrogen-containing tetracyclic compound, preparation method therefor, and medical use thereof
|
|
EP4426695A1
(en)
|
2021-11-05 |
2024-09-11 |
Frontier Medicines Corporation |
Kras g12c inhibitors
|
|
TW202340212A
(zh)
|
2021-11-24 |
2023-10-16 |
美商建南德克公司 |
治療性化合物及其使用方法
|
|
TW202332429A
(zh)
|
2021-11-24 |
2023-08-16 |
美商建南德克公司 |
治療性化合物及其使用方法
|
|
WO2023099624A1
(en)
|
2021-12-01 |
2023-06-08 |
Boehringer Ingelheim International Gmbh |
Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
|
|
EP4442686A4
(en)
*
|
2021-12-02 |
2025-10-22 |
Abbisko Therapeutics Co Ltd |
KRAS INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL USE
|
|
WO2023114954A1
(en)
|
2021-12-17 |
2023-06-22 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
|
US20250163039A1
(en)
|
2021-12-22 |
2025-05-22 |
Boehringer Ingelheim International Gmbh |
Heteroaromatic compounds for the treatment of cancer
|
|
US20250161305A1
(en)
|
2021-12-28 |
2025-05-22 |
Astrazeneca Uk Limited |
Combination of antibody-drug conjugate and rasg12c inhibitor
|
|
CN114409653A
(zh)
*
|
2021-12-31 |
2022-04-29 |
苏州闻天医药科技有限公司 |
一种桥环并嘧啶并环类化合物及其用途
|
|
WO2023138583A1
(zh)
*
|
2022-01-21 |
2023-07-27 |
上海湃隆生物科技有限公司 |
杂环类化合物、药物组合物及其应用
|
|
EP4227307A1
(en)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
|
WO2023154528A1
(en)
*
|
2022-02-11 |
2023-08-17 |
Wave Life Sciences Ltd. |
Stereoselective technologies for chiral compounds
|
|
EP4489755A1
(en)
|
2022-03-08 |
2025-01-15 |
Revolution Medicines, Inc. |
Methods for treating immune refractory lung cancer
|
|
EP4489738A1
(en)
|
2022-03-11 |
2025-01-15 |
Kumquat Biosciences Inc. |
Heterocyclic compounds and uses thereof
|
|
KR20250093430A
(ko)
|
2022-03-25 |
2025-06-24 |
일라이 릴리 앤드 캄파니 |
Kras 억제제
|
|
CA3244999A1
(en)
|
2022-03-31 |
2025-06-13 |
Eisai R&D Management Co., Ltd. |
Pharmaceutical composition for treating tumors
|
|
JP2025511161A
(ja)
|
2022-04-04 |
2025-04-15 |
サノフイ |
Ｋｒａｓ ｇ１２ｃ阻害剤及びｔｅａｄ阻害剤の治療的組合せ
|
|
WO2023199180A1
(en)
|
2022-04-11 |
2023-10-19 |
Novartis Ag |
Therapeutic uses of a krasg12c inhibitor
|
|
KR20250003858A
(ko)
*
|
2022-04-18 |
2025-01-07 |
미라티 테라퓨틱스, 인크. |
아다그라십의 합성을 위한 방법 및 중간체
|
|
TW202406927A
(zh)
|
2022-05-06 |
2024-02-16 |
日商中外製藥股份有限公司 |
相對於ｈｒａｓ與ｎｒａｓ具有選擇性之ｋｒａｓ抑制作用的環狀化合物
|
|
CN114907387B
(zh)
*
|
2022-05-26 |
2023-11-10 |
中山大学 |
嘧啶并吡咯类kras抑制剂及其制备方法与应用
|
|
CN117164526A
(zh)
*
|
2022-05-27 |
2023-12-05 |
苏州泽璟生物制药股份有限公司 |
2-(哌嗪-2-基)乙腈类衍生物及其制备方法和应用
|
|
CN117164580A
(zh)
*
|
2022-05-27 |
2023-12-05 |
苏州泽璟生物制药股份有限公司 |
一种kras g12c抑制剂的制备方法及其中间体
|
|
JP2025522388A
(ja)
|
2022-06-10 |
2025-07-15 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｋｒａｓ阻害剤としてのテトラヒドロピリド３，４－ｄピリミジン誘導体
|
|
AU2023285116A1
(en)
|
2022-06-10 |
2024-12-19 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
WO2024031088A1
(en)
|
2022-08-05 |
2024-02-08 |
Kumquat Biosciences Inc. |
Heterocyclic compounds and uses thereof
|
|
JP2025528836A
(ja)
|
2022-08-17 |
2025-09-02 |
ツリーライン バイオサイエンシズ インコーポレイテッド |
ピリドピリミジンＫＲａｓ阻害剤
|
|
CN120112284A
(zh)
|
2022-08-19 |
2025-06-06 |
米拉蒂治疗股份有限公司 |
阿达格拉西布固体药物组合物
|
|
GB202212641D0
(en)
|
2022-08-31 |
2022-10-12 |
Jazz Pharmaceuticals Ireland Ltd |
Novel compounds
|
|
KR20250116016A
(ko)
|
2022-11-09 |
2025-07-31 |
레볼루션 메디슨즈, 인크. |
화합물, 복합체 및 이들의 제조 및 사용 방법
|
|
TW202430179A
(zh)
|
2022-11-21 |
2024-08-01 |
美商樹線生物科學公司 |
螺環二氫哌喃并嘧啶ＫＲａｓ抑制劑
|
|
CN116789609A
(zh)
*
|
2023-03-03 |
2023-09-22 |
南京优氟医药科技有限公司 |
一种(r)-2-(哌嗪-2-基)乙腈盐酸盐的制备方法
|
|
CN116768804A
(zh)
*
|
2023-03-15 |
2023-09-19 |
南京优氟医药科技有限公司 |
一种(s)-2-(哌嗪-2-基)乙腈盐酸盐的制备方法
|
|
KR20250164828A
(ko)
|
2023-03-30 |
2025-11-25 |
레볼루션 메디슨즈, 인크. |
Ras gtp 가수분해 유도를 위한 조성물 및 이의 용도
|
|
CN121079301A
(zh)
|
2023-03-30 |
2025-12-05 |
伊莱利利公司 |
Kras抑制剂
|
|
US20240368193A1
(en)
|
2023-03-31 |
2024-11-07 |
Eli Lilly And Company |
Kras inhibitors
|
|
EP4656193A1
(en)
|
2023-04-06 |
2025-12-03 |
Eisai R&D Management Co., Ltd. |
Pharmaceutical composition for treating tumors
|
|
AU2024243852A1
(en)
|
2023-04-07 |
2025-11-06 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
WO2024211663A1
(en)
|
2023-04-07 |
2024-10-10 |
Revolution Medicines, Inc. |
Condensed macrocyclic compounds as ras inhibitors
|
|
TW202448897A
(zh)
|
2023-04-14 |
2024-12-16 |
美商銳新醫藥公司 |
Ｒａｓ抑制劑之結晶形式、含有其之組合物及其使用方法
|
|
CN121100123A
(zh)
|
2023-04-14 |
2025-12-09 |
锐新医药公司 |
Ras抑制剂的结晶形式
|
|
WO2024229444A2
(en)
*
|
2023-05-04 |
2024-11-07 |
Frontier Medicines Corporation |
Mutant kras inhibitors and uses thereof
|
|
AU2024265078A1
(en)
|
2023-05-04 |
2025-12-11 |
Revolution Medicines, Inc. |
Combination therapy for a ras related disease or disorder
|
|
AU2024276994A1
(en)
|
2023-05-24 |
2025-10-23 |
Kumquat Biosciences Inc. |
Heterocyclic compounds and uses thereof
|
|
TW202510886A
(zh)
|
2023-05-31 |
2025-03-16 |
德商百靈佳殷格翰國際股份有限公司 |
作為用於預測癌症治療反應性之生物標記之存活素
|
|
CN116675690A
(zh)
*
|
2023-06-02 |
2023-09-01 |
北京康立生医药技术开发有限公司 |
一种肺癌治疗药物的制备方法
|
|
CN116478141B
(zh)
*
|
2023-06-20 |
2023-10-24 |
药康众拓(江苏)医药科技有限公司 |
氘代kras抑制剂药物及用途
|
|
TW202502779A
(zh)
|
2023-06-30 |
2025-01-16 |
美商金橘生物科技公司 |
取代的雜芳族胺及其用途
|
|
WO2025019688A2
(en)
*
|
2023-07-20 |
2025-01-23 |
Mirati Therapeutics, Inc. |
Crystalline forms of salts of adagrasib
|
|
US20250049810A1
(en)
|
2023-08-07 |
2025-02-13 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
TW202528315A
(zh)
|
2023-09-21 |
2025-07-16 |
美商樹線生物科學公司 |
螺環二氫哌喃并吡啶ＫＲａｓ抑制劑
|
|
US20250101043A1
(en)
|
2023-09-27 |
2025-03-27 |
Eli Lilly And Company |
Kras inhibitors
|
|
WO2025080946A2
(en)
|
2023-10-12 |
2025-04-17 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
TW202535891A
(zh)
|
2023-10-20 |
2025-09-16 |
美商默沙東有限責任公司 |
Ｋｒａｓ蛋白之小分子抑制劑
|
|
US20250205238A1
(en)
|
2023-12-20 |
2025-06-26 |
Boehringer Ingelheim International Gmbh |
Anti-cancer combination therapy
|
|
US20250215087A1
(en)
|
2023-12-29 |
2025-07-03 |
Bristol-Myers Squibb Company |
Combination therapy of kras inhibitor and treg depleting agent
|
|
WO2025171055A1
(en)
|
2024-02-06 |
2025-08-14 |
Kumquat Biosciences Inc. |
Heterocyclic conjugates and uses thereof
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025230971A1
(en)
|
2024-04-30 |
2025-11-06 |
Kumquat Biosciences Inc. |
Macrocyclic heterocycles as anticancer agents
|
|
WO2025240847A1
(en)
|
2024-05-17 |
2025-11-20 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025245127A1
(en)
|
2024-05-21 |
2025-11-27 |
Treeline Biosciences, Inc. |
Spirocyclic dihydropyranopyrimidine kras inhibitors
|
|
WO2025242126A1
(zh)
*
|
2024-05-22 |
2025-11-27 |
上海正大天晴医药科技开发有限公司 |
一种药物组合及其应用
|
|
WO2025255438A1
(en)
|
2024-06-07 |
2025-12-11 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|